Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness

J. Gelžinský, O. Mayer, J. Seidlerová, M. Mateřánková, Š. Mareš, V. Kordíková, L. Trefil, R. Cífková, J. Filipovský

. 2020 ; 43 (2) : 111-120. [pub] 20191021

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020775

Grantová podpora
NV15-27109A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK ProQuest Central od 2015-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2015-01-01 do Před 1 rokem

Odkazy

PubMed 31636359
DOI 10.1038/s41440-019-0347-y
Knihovny.cz E-zdroje

Circulating levels of soluble receptor for advanced glycation end-products (sRAGE) have been suggested to have a protective role in neutralizing advanced glycation end-products (AGEs) and their pathological effects on vessel walls. We aimed to investigate the association between the circulating concentration of sRAGE and the dynamics of arterial wall stiffening as a manifestation of vascular aging in the general population. In a prospective cohort study, we longitudinally followed 530 general-population-based subjects (subsample of Czech post-MONICA study). Aortic pulse wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE were assessed at baseline by ELISA (R&D Systems). The average ∆PWV/year significantly decreased across the sRAGE quintiles (p = 0.048), and a drop by one sRAGE quintile was associated with an ~21% increase in the relative risk of accelerated age-dependent stiffening (∆PWV/year ≥ 0.2 m/s). Subjects in the bottom quintile of sRAGE (<889.74 pg/mL) had a fully adjusted odds ratio of accelerated stiffening of 1.72 (95% CI: 1.06-2.79), p = 0.028, while those with high sRAGE concentrations (≥1695.2 pg/mL) showed the opposite effect [odds ratio 0.55 (95% CI: 0.33-0.90), p = 0.017]. In conclusion, the circulating status of sRAGE independently influenced the individual progression of arterial stiffness over time. This finding strongly supports the hypothesis that high sRAGE has a protective role against vascular aging.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020775
003      
CZ-PrNML
005      
20210830102425.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41440-019-0347-y $2 doi
035    __
$a (PubMed)31636359
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Gelžinský, Július $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
245    10
$a Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness / $c J. Gelžinský, O. Mayer, J. Seidlerová, M. Mateřánková, Š. Mareš, V. Kordíková, L. Trefil, R. Cífková, J. Filipovský
520    9_
$a Circulating levels of soluble receptor for advanced glycation end-products (sRAGE) have been suggested to have a protective role in neutralizing advanced glycation end-products (AGEs) and their pathological effects on vessel walls. We aimed to investigate the association between the circulating concentration of sRAGE and the dynamics of arterial wall stiffening as a manifestation of vascular aging in the general population. In a prospective cohort study, we longitudinally followed 530 general-population-based subjects (subsample of Czech post-MONICA study). Aortic pulse wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE were assessed at baseline by ELISA (R&D Systems). The average ∆PWV/year significantly decreased across the sRAGE quintiles (p = 0.048), and a drop by one sRAGE quintile was associated with an ~21% increase in the relative risk of accelerated age-dependent stiffening (∆PWV/year ≥ 0.2 m/s). Subjects in the bottom quintile of sRAGE (<889.74 pg/mL) had a fully adjusted odds ratio of accelerated stiffening of 1.72 (95% CI: 1.06-2.79), p = 0.028, while those with high sRAGE concentrations (≥1695.2 pg/mL) showed the opposite effect [odds ratio 0.55 (95% CI: 0.33-0.90), p = 0.017]. In conclusion, the circulating status of sRAGE independently influenced the individual progression of arterial stiffness over time. This finding strongly supports the hypothesis that high sRAGE has a protective role against vascular aging.
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a stárnutí $x metabolismus $7 D000375
650    _2
$a krevní tlak $x fyziologie $7 D001794
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a analýza pulzové vlny $7 D063177
650    _2
$a receptor pro konečné produkty pokročilé glykace $x krev $7 D000067759
650    _2
$a tuhost cévní stěny $x fyziologie $7 D059289
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mayer, Otto $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic. mayero@fnplzen.cz $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. mayero@fnplzen.cz
700    1_
$a Seidlerová, Jitka $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Mateřánková, Markéta $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Mareš, Štěpán $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Kordíková, Veronika $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Trefil, Ladislav $u Department of Clinical Biochemistry and Hematology, University Hospital, Pilsen, Czech Republic
700    1_
$a Cífková, Renata $u Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Filipovský, Jan $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
773    0_
$w MED00006041 $t Hypertension research : official journal of the Japanese Society of Hypertension $x 1348-4214 $g Roč. 43, č. 2 (2020), s. 111-120
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31636359 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102425 $b ABA008
999    __
$a ok $b bmc $g 1691368 $s 1141221
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 43 $c 2 $d 111-120 $e 20191021 $i 1348-4214 $m Hypertension research $n Hypertens Res $x MED00006041
GRA    __
$a NV15-27109A $p MZ0
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace